New Search

If you are not happy with the results below please do another search

1621 search results for:


Thermo Fisher Scientific, Advanced Electrophoresis Solutions agree to combine essential protein separation techniques with mass spectrometry

Thermo Fisher Scientific and Advanced Electrophoresis Solutions (AES), specialists in protein imaging technologies, have agreed to combine essential protein separation techniques with mass spectrometry (MS) to advance therapeutic protein development through streamlined characterization. Together, the companies will promote Thermo Fisher’s expertise as a leading provider of mass spectrometry technology for biopharma and proteomics applications, and AES’ ability […]


Selux Diagnostics receives additional $14.6 million in BARDA funding after successfully completing first clinical trial

Selux Diagnostics, which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, has been awarded an additional $14.6 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and […]


INTEGRA Biosciences takes significant step towards sustainability

INTEGRA Biosciences has made significant progress towards its goal of minimizing its ecological footprint with the installation of new photovoltaic systems at the company’s US facilities in Hudson, NH. These systems will provide 77 percent of the total energy requirement for both the company’s US headquarters and production centre, saving as much CO2 as 2900 cars […]


SignalChem enters clinical trial collaboration with Merck to evaluate effect of SLC-391 in combination with pembrolizumab in advanced NSLC

SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, is collaborating with Merck (MSD) through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC).


Phico Therapeutics awarded up to $18.2 million to advance SASPject antibacterial therapy through Phase 1 clinical trials

Phico Therapeutics, a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to US$18.2 million from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research.


ENPICOM and Viroclinics-DDL receive joint MIT Zuid subsidy to accelerate and improve antibody and vaccine discovery and development

Viroclinics-DDL, a Contract Research Organization specialized in molecular diagnostic testing and assay development, and ENPICOM, a bioinformatics software engineering company, have received approval of their joint MIT Zuid subsidy (SME Innovation Stimulation Top Sectors South Holland) application. This R&D partnership project combines ‘wet-lab’ (in vitro) diagnostic and high-throughput sequencing expertise of Viroclinics-DDL and ‘dry-lab’ (in […]